On Aug. 25, 2003, the FDA approved an expanded indication for ENBREL (etanercept) to inhibit the progression of structural damage of active arthritis in patients with psoriatic arthritis. The approval was announced by Amgen and Wyeth Pharmaceuticals. ENBREL was the first and only approved therapy for both the inhibition of structural damage and the reduction in signs and symptoms of patients with psoriatic arthritis.